Stockwinners Market Radar for May 07, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:25 EDT Shenandoah COO buys $149.5K in common stock - In a regulatory filing, Shenandoah disclosed that its COO Edward McKay bought 10K shares of common stock on May 7th in a total transaction size of $149.5K.

19:50 EDT Inspire Veterinary Partners Inc trading halted, news pending

19:21 EDT Innodata awarded expansion of LLM development program - Innodata is announcing today that it has been awarded an expansion of one of its large language model, or LLM, development programs by one of its existing "Magnificent Seven" Big Tech customers. Innodata anticipates that the expansion will result in approximately $23.5 million of additional annualized run rate revenue once implemented. This is in addition to the $20 million in new programs with this customer Innodata announced on April 24, 2024. Innodata expects that these programs will ramp up over the next two months. While our customer agreements typically contain early-termination-upon-notice provisions, Innodata believes this customer is committed to a significant, multi-year LLM strategy from which Innodata stands to benefit. CEO Jack Abuhoff says: ""This significant customer expansion demonstrates the incredible results we are creating for our customers. One of our large Big Tech customers has stated that the quality of instruction data sets, one of a broad range of services Innodata provides to support generative AI programs, has an outsized influence on the performance of their LLM models and some of their biggest improvements in model quality are due to carefully crafted instruction data sets."

18:27 EDT B2Gold says on track to meet annual gold production forecast - Based on the positive first quarter of 2024 operating and financial results, B2Gold is on track to meet its annual gold production forecast of between 860,000 and 940,000 ounces (including 40,000 to 50,000 attributable ounces from Calibre). The Company's total consolidated gold production is expected to be relatively consistent throughout 2024, with third quarter production expected to be slightly lower. The expected decrease in gold production relative to 2023 is predominantly due to lower production at the Fekola Complex as a result of the delay in receiving an exploitation license for Fekola Regional from the Government of Mali, delaying the 80,000 to 100,000 ounces that were scheduled in the life of mine plan to be trucked to the Fekola mill and processed in 2024. The contribution of this gold production from Fekola Regional is now expected to start at the beginning of 2025. The Company's total consolidated cash operating costs for the year (including estimated attributable results for Calibre) are forecast to be between $835 and $895 per ounce and total consolidated all-in sustaining costs (including estimated attributable results for Calibre) are forecast to be between $1,360 and 1,420 per ounce. The anticipated increase in the Company's consolidated cash operating costs per ounce for 2024 reflects the processing of lower-grade ore at Fekola in 2024. The total all-in sustaining costs per ounce for 2024 reflect the final full year of spending on both the new Fekola tailings storage facility and the Fekola solar plant expansion, in addition to the ongoing substantial capitalized stripping campaign planned at Fekola for 2024.

18:17 EDT Digi International announces court found invalid patent claims made by Airgain - Digi International (DGII) announced that the U.S. District Court for the District of Minnesota has found all patent claims asserted by NimbeLink Corporation against Digi International to be invalid. NimbeLink is a subsidiary of Airgain (AIRG). In a lawsuit filed in September 2022, the Airgain subsidiary had alleged that certain Digi products infringed two patents related to NimbeLink's Skywirecellular modems. On March 14 the Court issued a ruling rendering all of NimbeLink's asserted patent claims invalid.

17:49 EDT Qiagen enters CRADA with FBI for QIAcuity digital PCR devices - Qiagen announced a cooperative research and development agreement, or CRADA, with the U.S. Federal Bureau of Investigation, or FBI, to develop a novel test for its QIAcuity digital PCR devices that will boost forensics by improving the quantification of DNA in human samples. The collaboration aims to develop a first-of-its-kind digital PCR assay that can simultaneously quantify in absolute terms nuclear and mitochondrial DNA concentrations, male DNA, and include quality markers for degradation and inhibition.

17:35 EDT Cricut announces 40c per share special dividend, $50M stock repurchase plan - "Given the confidence in the sustainability of our profitable operations, the board of directors approved three capital allocation items: a special dividend of $0.40 per share, a recurring semi-annual dividend of $0.10 per share, and another $50 million stock repurchase program." said Kimball Shill, Chief Financial Officer of Cricut. "We delivered our 21st consecutive quarter of positive net income and continue to generate healthy cash flow. In Q1 2024, we generated $57 million in cash from operations, ended the quarter with $282 million in cash and cash equivalents, and we remain debt free. We remain committed to our long-term operating margin targets of 15-19%. Our proven model has demonstrated that when we operate at scale and drive top line growth, these margins are achievable."

17:21 EDT Leafly appoints Peter Lee as COO - Leafly Holdings announced that Peter Lee will join Leafly as President and COO, leading new monetization efforts, operations, and corporate development, and deepening partnerships with Leafly's customers. He will remain a member of Leafly's Board of Directors. Peter brings more than 25 years of strategic leadership and more than 5 years of cannabis industry experience as well as deep knowledge of both public markets and public equities. Peter served as President, Chief Financial Officer and member of the board of directors of Merida Merger Corporation until it merged with and into Leafly as part of Leafly's go-public transaction in 2022. Peter has been a member of Leafly's Board of Directors ever since. From 2011 to 2018, he co-founded and was a Managing Partner at Sentinel Rock Capital, a long/short equity-oriented hedge fund. He has held various roles at other long/short equity-oriented hedge funds at Spring Point Capital, Blackstone Kailix, and Tiger Management. Peter started his career as an analyst at Morgan Stanley Capital Partners, the private equity investment fund of Morgan Stanley. He received a B.S. in Business Administration from the University of California, Berkeley Haas School of Business and an MBA from Stanford Graduate School of Business.

17:09 EDT AdTheorent announces expiration of waiting period for Cadent acquisiton - AdTheorent Holding Company announced the expiration of the waiting period under the Hart-Scott-Rodino, HSR, Antitrust Improvements Act of 1976, with respect to the previously announced agreement for the Company to be acquired by Cadent for $3.21 per share in cash, or approximately $324M. The HSR waiting period expired at 11:59 p.m. on May 6, which was a condition to the closing of the pending transaction.

17:05 EDT Toast up 5% at $24.81 after Q1 results, guidance raise

17:01 EDT U.S. Physical Therapy raises FY24 adjusted EBITDA view to $82.5M-$87.5M - Management currently expects Adjusted EBITDA for 2024 to be in the range of $82.5 million to $87.5 million. The $2.5 million increase in guidance is attributable to the change in the Medicare rate reduction from 3.5%, which was effective from January 1 through March 8, to 1.8% effective March 9, as adjusted by the Consolidated Appropriations Act of 2024, as well as the Company's strong performance in the 2024 First Quarter relative to management's expectations. Consistent with the previously-provided guidance, the updated guidance includes the expected EBITDA contribution from acquisitions that either have closed or are expected to close in or shortly after the first half of 2024.

16:47 EDT ZoomInfo board approves additional $500M under share repurchase program - The Board of Directors of ZoomInfo approved an additional $500 million under the share repurchase program, bringing the total aggregate authorization to $1.1 billion, of which $546.8 million remained outstanding as of quarter-end.

16:46 EDT Arista Networks announces additional $1.2B stock repurchase program - Arista Networks said it now completed repurchases of its common stock totaling $2B under previous stock repurchase programs. On May 3, Arista's board authorized an additional program to repurchase up to $1.2B.

16:45 EDT Montana Technologies Corp. announces senior leadership appointments - Montana Technologies Corp. announced that it has appointed the following financial and legal executives to its management team: Stephen Pang, Chief Financial Officer; Chad MacDonald, Chief Legal Officer; and Tom Divine, Vice President, Investor Relations and Finance. In conjunction with these new appointments, Jeff Gutke, who since 2021 served as the Chief Financial Officer of Montana's predecessor company, Montana Technologies LLC, is transitioning into the new role of Chief Administrative Officer at Montana. The management team will also include Pat Eilers, the Chairman of Montana's Board of Directors, who has been named Montana's Executive Chairman.

16:42 EDT Lyft sees Q2 adjusted EBITDA $95M-$100M - Sees Q2 gross bookings roughly $4B-$4.1B.

16:40 EDT Invitae receives court approval for sale to Labcorp - Labcorp and Invitae announced that the United States Bankruptcy Court has approved the previously announced bid by Labcorp to acquire assets of Invitae. Pursuant to the asset purchase agreement, Labcorp will acquire select assets of Invitae on a going concern basis for $239M in cash consideration, plus other non-cash consideration. Invitae and Labcorp anticipate the sale will be completed in the third quarter of 2024, subject to customary closing conditions and applicable regulatory approvals.

16:38 EDT Healthpeak Properties announces JV wind-down - Healthpeak Properties and King Street Properties announced that Healthpeak has acquired KSP's minority interest in the joint ventures in eight lab buildings in Cambridge and Lexington, Massachusetts. Healthpeak will assume day-to-day management of the buildings following a short-term transition period. "King Street has been a key strategic partner of Healthpeak's since 2017," said Scott Brinker, Healthpeak's President and CEO. "Our successful partnership grew to 900,000 square feet across four campuses." Mr. Brinker continued, "Healthpeak's greater Boston portfolio now totals 2.7 million square feet, giving us the scale to internalize. We would like to thank the KSP team for many years of outstanding partnership and mutual success." "Seven years ago, we and Healthpeak formed a joint venture to maximize the development potential of a portion of King Street's Boston portfolio of Class A life science projects," said Thomas Ragno, King Street's Founder/Principal. "We enjoyed working with the Healthpeak team to meet that goal and today marks the culmination of this innovative approach, which has proven to be highly successful for both firms."

16:36 EDT International Paper says 'no comment' of rumors, speculation in recent media - Consistent with its standing practice, International Paper offers no comment on rumors or speculation contained in recent media reports. The IP team, led by new CEO Andy Silvernail, is executing on business strategies and pursuing commercial and cost improvement initiatives across the portfolio to achieve best-in-class profit margins and significant earnings growth. In addition, as industry conditions continue to improve, IP will come out of a cyclical bottom for earnings. The company is also focused on completing its previously announced combination with DS Smith, which offers a unique and highly compelling opportunity to create significant shareholder value above its base plan.

16:34 EDT Planet Green Holdings receives audit opinion with going concern explanation - Planet Green Holdings announced that, as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2023, which was filed on April 1, 2023 with the SEC, the audited financial statements contained an unqualified audit opinion from its independent registered public accounting firm that included an explanatory paragraph related to the company's ability to continue as a going concern.

16:30 EDT HASI, KKR establish $2B strategic partnership over sustainability projects - Hannon Armstrong (HASI) and KKR (KKR) announced an agreement to establish CarbonCount Holdings 1 LLC ("CCH1") to invest up to a combined $2 billion in climate positive projects across the United States. Per the agreement, signed May 4, 2024, HASI and KKR have each made an initial capital commitment of up to $1 billion to CCH1, to invest up to an aggregate of $2 billion in clean energy assets over the next 18 months. HASI will source the investments for and manage CCH1, remain the interface with its clients, and measure the avoided emissions of all investments in CCH1 using its proprietary CarbonCount(R) scoring tool. These investments will be consistent with HASI's existing investment strategy which is focused on behind-the-meter, grid-connected, renewable natural gas and transport projects. At close, CCH1 will be seeded with assets representing approximately 10% of the up to $2 billion total committed amounts. "Our strategic partnership with KKR perfectly aligns with our Climate Clients Assets strategy, enabling us to capitalize on our ambitious pipeline of opportunities and scale our business," said Jeffrey A. Lipson, President and Chief Executive Officer of HASI. "We are excited to collaborate with the KKR team, who share our commitment to accelerating the energy transition and whose interest in the relationship serves as a testament to HASI's history of success."

16:28 EDT Olo partners with Dutch Bros to offer mobile app ordering and payment - Dutch Bros (BROS) has "selected Olo (OLO) to enable seamless ordering and payment through its mobile app for the first time. Rolling out across all of its locations nationwide, Dutch Bros will deploy Olo Order and Pay to boost operational efficiency at the drive-thru and streamline the ordering and payment experience for guests. Anticipating availability brand-wide by the end of this year, Dutch Bros digital ordering and payment capabilities will empower guests with the ability to order and pay for their favorite beverages before arriving at the drive-thru from their own mobile device. Not only will this appeal to guests seeking speed and convenience, but it will also expedite the transaction process for employees. For added ease, Olo's flexible platform allows payment via Google Pay and Apple Pay in Mobile Wallets. In addition, Olo's Order and Pay products easily integrate into Dutch Bros' existing mobile app and Dutch Rewards program, ensuring no interruption to the millions of guests already enrolled."

16:25 EDT Nextdoor names Marissa Mayer, Niraj Shah, Robert Hohman to board - Nextdoor Holdings (KIND) announced the appointment of three additional members to its board of directors: Marissa Mayer, Founder/CEO of Sunshine and former President and Chief Executive Officer of Yahoo!, Niraj Shah, Chief Executive Officer, Co-Chairman and Co-Founder of Wayfair (W), and Robert Hohman, Co-Founder and Chairman of Glassdoor. "We are delighted to welcome Ms. Mayer, Mr. Shah, and Mr. Hohman to Nextdoor's board. Each of these executives has significant experience leading successful technology companies at scale," said Nirav Tolia, Nextdoor Executive Chair and incoming CEO. "With proven product-centric operational expertise, we are thrilled that they have chosen to join Nextdoor's board at this exciting time."

16:22 EDT Aris Water Solutions sees Q2 adjusted EBITDA $44M-$48M - Sees Q2 CapEx $38M-$43M. Sees Produced Water Handling volumes between 1,015 and 1,045 thousand barrels of water per day and Water Solutions volumes between 400 and 430 thousand barrels of water per day.

16:22 EDT Aris Water Solutions board increases quarterly dividend 17% to 10.5c per share - On April 30, 2024, Aris's Board of Directors approved a 17% increase to Aris's quarterly dividend to 10.5c per share. In conjunction with the dividend payment, a distribution of 10.5c per unit will be paid to unit holders of Solaris Midstream Holdings, LLC. The dividend will be paid on June 20, 2024, to holders of record of the company's Class A common stock as of the close of business on June 6, 2024. The distribution to unit holders of Solaris Midstream Holdings, LLC will be subject to the same payment and record dates.

16:20 EDT Baldwin Group changing ticker symbol to BWIN - The Baldwin Group, the go-to-market brand name for The Baldwin Insurance Group, formerly BRP Group (BRP), says that in concert with the company's rebranding to The Baldwin Group, the company will be changing its ticker symbol to "BWIN." The ticker symbol change will not take effect until the beginning of trading on NASDAQ on May 20.

16:19 EDT One Group Hospitality did not repurchase any shares during Q1

16:14 EDT Permian Resources boosts 2024 standalone oil, production targets - Based on recent operational results, Permian Resources increased its 2024 standalone oil and total production targets by approximately 2% to 148-152 MBbls/d and 310-330 MBoe/d, respectively, based on the mid-point of guidance. There are no other changes to the Company's standalone guidance ranges. The recent acquisitions noted above are expected to add approximately 3,500 Boe/d (~45% oil) of total production during the second half of 2024. The Company expects approximately $50 million of incremental capital expenditures associated with wells spud on the newly acquired acreage during the second half of 2024

16:12 EDT Arko Corp. increases share repurchase program to $125M - Kotler continued: "We firmly believe our current valuation does not fully reflect the underlying value of our business, which has grown to become one of the largest convenience store operators in the United States and a Fortune 500 company. Given this disconnect, I am pleased to announce that the Board has approved an expansion of our share repurchase program to $125 million, which we believe will support long-term value creation for our valued stockholders."

16:09 EDT iRobot appoints Gary Cohen as CEO - iRobot announced that Gary Cohen will serve as the company's new CEO, effective immediately. Cohen has more than 25 years of executive leadership and turnaround experience. As iRobot CEO, he will lead the company's transformational strategy to re-orient toward profitability following a recent operational restructuring. Cohen will be responsible for overseeing all aspects of the company's business, including innovation, product and commercial strategies, operational excellence, talent, and maintaining a sustainable competitive advantage and consumer-centric brand. Cohen has successfully driven enterprise-wide transformation and brand growth at Fortune 500 and privately held companies in both consumer and B2B segments. He has a history of leading successful turnarounds, most recently at Qualitor Automotive. Prior to Qualitor Automotive, Mr. Cohen served as CEO at Timex, where he led an $800M multi-brand business and global team of 5,000 employees, increasing sales through the development of a new advertising platform as well as a blueprint for product innovation and restructuring of its product portfolio. Mr. Cohen will join iRobot's board of directors after its annual shareholder meeting on May 23. Andrew Miller will remain as chair. Former interim CEO Glen Weinstein will stay on with the company for 60 days to assist in the leadership transition.

16:06 EDT Staar Surgical announces milestone strategic agreement in U.S. with IQ Laser - STAAR Surgical Company announces another milestone achieved on its U.S. Highway 93 go-to-market program - a strategic agreement with IQ Laser Vision, a leader in providing clear vision to clients with locations across California and Texas, and a top EVO ICL practice in North America.

16:01 EDT Upstart Holdings trading halted, news pending

15:55 EDT BigCommerce jumps 10% after Reuters says company draws takeover interest

14:26 EDT NVR authorizes repurchase of up $750M of outstanding common stock - NVR, Inc. announced that its board of directors has authorized the repurchase of up to an aggregate of $750M of its outstanding common stock. The repurchase authorization does not have an expiration date. "The purchases will occur from time to time in the open market and/or in privately negotiated transactions as market conditions permit. The company indicated that the authorization is a continuation of the stock repurchase program that began in 1994 and is consistent with NVR's strategy of maximizing shareholder value," NVR stated.

14:04 EDT ESPN BET named official sports betting sponsor of PGA Championship through 2026 - The PGA of America and PENN Entertainment announced a multiyear sports betting partnership. Under the agreement, ESPN BET becomes the "Official Sports Betting Sponsor" of the PGA Championship through 2026. The 2024 PGA Championship will take place at Valhalla Golf Club in Louisville, Kentucky from May 16-19. "This agreement marks a milestone for the PGA Championship as it becomes the first men's golf major to establish an official sports betting sponsor. ESPN BET is a best-in-class online sportsbook that combines PENN's proprietary in-house technology and deep sportsbook operational expertise with ESPN's industry-leading brand and multiplatform reach," the company and PGA stated. Reference Link

13:59 EDT T-Mobile to offer new iPad Pro, iPad Air - T-Mobile (TMUS) said it will offer the new iPad Pro (AAPL) in a thin and light design, with a breakthrough Ultra Retina XDR display, and fast M4 chip with powerful AI capabilities; in addition to the redesigned 11-inch and all-new 13-inch iPad Air, supercharged by the M2 chip delivering phenomenal performance and advanced capabilities. Customers will be able to order the new iPad Pro and iPad Air starting Friday, May 10, with availability in stores beginning Wednesday, May 15.

12:33 EDT Grifols board adopts resolutions to strengthen governance - Grifols says its board has unanimously adopted "resolutions in order to further strengthen its corporate governance system," including the update of its related party transactions policy, the approval of a competency matrix of the board as an internal tool to analyze the strengths and needs of the board's composition and the approval of internal regulations for the Appointments and Remunerations Committee.

12:05 EDT Remitly Global appoints Ronit Peled as CPO - Remitly Global announced the appointment of Ronit Peled as Chief People Officer. Most recently serving as Chief People Officer of DreamBox Learning, a prominent K-12 educational technology company, Peled led the people function and championed operational efficiency during a time of rapid growth. Ronit will report to Remitly's EVP of Customer and Culture, Rene Yoakum.

12:01 EDT Zeta Global rises 17.6% - Zeta Global is up 17.6%, or $2.29 to $15.29.

12:00 EDT Paymentus falls -16.7% - Paymentus is down -16.7%, or -$3.71 to $18.49.

12:00 EDT Jeld-Wen falls -24.2% - Jeld-Wen is down -24.2%, or -$4.61 to $14.43.

11:35 EDT Nintendo president says Switch successor to be announced within this fiscal year - In a post on X, formerly Twitter, Nintendo president Shuntaro Furukawa said, "We will make an announcement about the successor to Nintendo Switch within this fiscal year. It will have been over nine years since we announced the existence of Nintendo Switch back in March 2015. We will be holding a Nintendo Direct this June regarding the Nintendo Switch software lineup for the latter half of 2024, but please be aware that there will be no mention of the Nintendo Switch successor during that presentation." Reference Link

11:19 EDT Vanda confirms receipt of revised takeover bid from Future Pak - Vanda Pharmaceuticals confirmed that it has received a revised unsolicited proposal from Future Pak to acquire the company. The revised proposal consists of a $7.25 to $7.75 per share in cash plus certain Contingent Value Rights, or "CVRs." The amended proposal follows Vanda's review and rejection of a prior unsolicited proposal from Future Pak to acquire the company for $7.25-$7.75 per share. "Consistent with its fiduciary duties, and in consultation with its independent financial and legal advisors, Vanda's board of directors will carefully review and evaluate the revised unsolicited proposal to determine the course of action that it believes is in the best interests of Vanda and its shareholders. Vanda does not intend to comment further on the revised, unsolicited proposal before the board has completed its review. There is no action for shareholders to take at this time," the company stated.

10:44 EDT Adtran: Confident in long-term outlook -

10:43 EDT HNR Acquisition says audit opinion includes going concern qualification - The audit opinion provided by the Company's independent public auditing firm relating to the Company's audited consolidated financial statements for the year ended December 31, 2023 included a going concern qualification. The financial statements were included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission on May 3, 2024. The opinion of the Company's independent public auditing firm notes that the Company has a significant working capital deficiency and needs to raise additional funds to meet its obligations and sustain its operations. The Company's independent public auditing firm indicated in its opinion that these conditions raise a substantial doubt about the Company's ability to continue as a going concern. Management's plans to alleviate this substantial doubt include improving profitability through streamlining costs, maintaining active hedge positions for its proven reserve production, and the issuance of additional shares of Class A common stock through under the Common Stock Purchase Agreement with White Lion Capital, LLC. The Company has a three-year Common Stock Purchase Agreement with a maximum funding limit of $150,000,000 that can fund the Company operations and production growth, and be used to reduce liabilities of the Company, subject to the Company's Registration Statement on Form S-1, which is in the review process, being declared effective by the Securities and Exchange Commission

10:42 EDT HNR Acquisition reports compliance with NYSE American Company Guie - HNR Acquisition announces its receipt of a letter from the NYSE American indicating the Company's compliance with Section 1007 of the NYSE American Company Guide following the Company's filing of its Annual Report on Form 10-K on May 3, 2024. Pursuant to the letter, the Company will be removed from the NYSE American's late filers' list and the "LF" indicator posted on the Company's "Profile, Data and News" page on the NYSE American website will be removed.

10:40 EDT Apple unveils new iPad Pro with M4 chip - Apple unveiled its new iPad Pro in "a stunningly thin and light design, taking portability and performance to the next level." Available in silver and space black finishes, the new iPad Pro comes in two sizes: a 13-inch model and an 11-inch model, Apple noted. "The new iPad Pro is made possible with the new M4 chip, the next generation of Apple silicon, which delivers a huge leap in performance and capabilities. M4 features an entirely new display engine to enable the precision, color, and brightness of the Ultra Retina XDR display. With a new CPU, a next-generation GPU that builds upon the GPU architecture debuted on M3, and the most powerful Neural Engine yet, the new iPad Pro is an outrageously powerful device for artificial intelligence," Apple stated. Customers can order the new iPad Pro with M4 starting today, May 7, in 29 countries and regions, including the U.S., with availability in stores beginning Wednesday, May 15, Apple stated. The 11-inch iPad Pro starts at $999 for the Wi-Fi model, and $1,199 for the Wi-Fi + Cellular model. The 13-inch iPad Pro starts at $1,299 for the Wi-Fi model, and $1,499 for the Wi-Fi + Cellular model in the U.S.

10:39 EDT Apple introduces Final Cut Pro for iPad 2 - Apple introduced Final Cut Pro for iPad 2, bringing huge updates that unleash the remarkable capabilities of the new iPad Pro and take creativity to the next level. Final Cut Pro for iPad 2 transforms iPad into a multicam production studio with Live Multicam, giving users the power to speed up their shoot by allowing them to connect and preview up to four cameras all at once, all in one place.1 To support Live Multicam, Final Cut Camera - an all-new video capture app - comes to iPhone and iPad, letting creators wirelessly connect and remotely direct each video angle with powerful pro controls.2 Final Cut Camera also works as a standalone professional video capture app on iPhone and iPad. External project support gives users the flexibility to edit projects directly from an external drive, leveraging the fast Thunderbolt connection of iPad Pro.3 Editing and finishing a project with Final Cut Pro on the new iPad Pro with the M4 chip is incredible, enabling users to color grade, apply multiple effects, and render graphically intense timelines even faster. Final Cut Pro for iPad 2 has even more customizable content for editing and creating unique projects, and leverages the advanced features of the all-new Apple Pencil Pro such as barrel roll and squeeze for Live Drawing. Final Cut Pro for iPad 2 will be available later this spring as a free update for existing users, and available on the App Store for $4.99 per month or $49 per year, with a one-month free trial for new users. Final Cut Camera will be available for free later this spring as a standalone app. Final Cut Pro for Mac 10.8 will be available as a free update for existing users and for $299.99 for new users on the Mac App Store. All new users can download a free 90-day trial of Final Cut Pro.

10:39 EDT Apple introduces M4 chip - Apple announced M4, the latest chip "delivering phenomenal performance to the all-new iPad Pro." Apple said: "Built using second-generation 3-nanometer technology, M4 is a system on a chip that advances the industry-leading power efficiency of Apple silicon and enables the incredibly thin design of iPad Pro. It also features an entirely new display engine to drive the stunning precision, color, and brightness of the breakthrough Ultra Retina XDR display on iPad Pro. A new CPU has up to 10 cores, while the new 10-core GPU builds on the next-generation GPU architecture introduced in M3, and brings Dynamic Caching, hardware-accelerated ray tracing, and hardware-accelerated mesh shading to iPad for the first time. M4 has Apple's fastest Neural Engine ever, capable of up to 38 trillion operations per second, which is faster than the neural processing unit of any AI PC today. Combined with faster memory bandwidth, along with next-generation machine learning accelerators in the CPU, and a high-performance GPU, M4 makes the new iPad Pro an outrageously powerful device for artificial intelligence." "The new iPad Pro with M4 is a great example of how building best-in-class custom silicon enables breakthrough products," said Johny Srouji, Apple's senior vice president of Hardware Technologies. "The power-efficient performance of M4, along with its new display engine, makes the thin design and game-changing display of iPad Pro possible, while fundamental improvements to the CPU, GPU, Neural Engine, and memory system make M4 extremely well suited for the latest applications leveraging AI. Altogether, this new chip makes iPad Pro the most powerful device of its kind."

10:34 EDT Apple introduces new Apple Pencil Pro - At this morning's Apple Event, Apple introduced the all new Apple Pencil Pro, which now supports Find My. The Pencil Pro pairs, charges, and stores on the side of the iPad magnetically.

10:25 EDT Celsius Holdings says taking 'conservative' approach to remainder of year - On its Q1 earnings conference call, Celsius said it continues to stick with its commentary from February where it noted that gross margins in the high 40s are very achievable, but "that we were not ready to move too far from that expectation until we got further into the year."

10:21 EDT Redwoods Acquisition Corp trading resumes

10:16 EDT Redwoods Acquisition Corp trading halted, volatility trading pause

10:13 EDT M8 Pharmaceuticals signs licensing agreement with Supernus - M8 Pharmaceuticals has signed an exclusive licensing agreement with Supernus Pharmaceuticals to seek regulatory approval and commercialize Qelbree under M8's trademark in Latin America. Qelbree which is approved in the United States is an extended-release formulation of viloxazine, a selective norepinephrine reuptake inhibitor to treat attention deficit hyperactivity disorder in adults and children 6 years of age and older. Unlike most ADHD medications on the market, this medication is a non-stimulant option. Qelbree is commercially available in the United States as a prescription medicine to treat ADHD in patients 6 years of age and older. Based on the results of four pivotal trials, Qelbree was approved by the US Food and Drug Administration in 2021 for the treatment of children 6-17 years of age and in 2022 for the treatment of adults. Qelbree is also currently being studied in several phase 4 clinical trials, the first of which is in combination with psychostimulants for the treatment of children and adolescents with ADHD. A second phase 4 clinical trial in preschool age children with ADHD is planned to commence in January 2024. A third phase 4 clinical trial is studying the impact of Qelbree on co-morbid mood symptoms prevalent in patients with ADHD. This strategic partnership is aligned with Acino's mission to provide Latin American patients access to innovative medicines and strengthen its leadership position in the central nervous system therapeutic space. The collaboration will provide prescribers with a new option to improve the ADHD treatment paradigm for millions of patients.

10:09 EDT Elastic, Red Hat announces expanded collaboration - Red Hat and Elastic (ESTC) announced an expanded collaboration to deliver next-generation search experiences supporting retrieval augmented generation patterns using Elasticsearch as a preferred vector database solution integrated on Red Hat OpenShift AI. With this collaboration, Red Hat and Elastic are providing enterprises with the tools they need to deliver, maintain and refine RAG solutions over time on a single, consistent platform.

10:01 EDT Myers Industries falls -18.7% - Myers Industries is down -18.7%, or -$4.29 to $18.70.

10:00 EDT Beyond falls -23.4% - Beyond is down -23.4%, or -$5.12 to $16.77.

10:00 EDT MoneyLion rises 17.5% - MoneyLion is up 17.5%, or $12.50 to $83.90.

09:47 EDT Jumia Technologies rises 16.3% - Jumia Technologies is up 16.3%, or 89c to $6.36.

09:47 EDT Zeta Global rises 19.8% - Zeta Global is up 19.8%, or $2.57 to $15.57.

09:47 EDT Teradata falls -15.9% - Teradata is down -15.9%, or -$6.03 to $31.93.

09:46 EDT Plutonian Acquisition Corp trading resumes

09:41 EDT Plutonian Acquisition Corp trading halted, volatility trading pause

09:35 EDT International Paper up 8% after Reuters report on Suzano takeover interest

09:31 EDT Performance Shipping signs shipbuilding contract for tanker vessel - Performance Shipping announced that, through a separate wholly-owned subsidiary, it has signed a shipbuilding contract with Jiangsu Yangzijiang Shipbuilding Group Co., Ltd., Jiangsu New Yangzi Shipbuilding Co., Ltd., and Jiangsu Yangzi Xinfu Shipbuilding Co., for the construction of a scrubber fitted 75,000 DWT LR1 chemical/product oil tanker for a contract price of US$54.1 million excluding extras and net of commission to third parties. 15% of the purchase price is payable upon receipt of a refund guarantee, expected to occur within 30 days; 10% of the purchase price is payable at each of the milestones of steel cutting, keel laying and launching of the vessel, and the remaining 55% of the purchase price is payable upon the vessel's delivery. The Company expects to take delivery of the vessel by January 2027. The vessel will be equipped with electronic main engines with high-pressure selective catalytic reactors for Tier IIIcompliance, exhaust gas cleaning systems for Tier II compliance, and ballast water treatment systems.

09:24 EDT GreenX targets 10 to 15 security token launches in 2024 - GreenX will be going for at least 10 tokenized offerings by end of year 2024, Chief Exchange Officer Philip Tam told IFN Investor, a leading digital Islamic finance publication. Philip Tam highlighted the next Security Token Offering, with initial tokenized listing around $20 mil, would be the largest gemstones collection in Southeast Asia, "These Real-World Assets- whether sapphire, rubies, emeralds or diamonds - each have a Gemological Research Association report to certify their intrinsic values." In accordance to its ESG initiative, GreenX would also be pushing for three green sustainable technology projects from Indonesia, including a perpetual electromagnet generator, waste engine oil to green diesel catalyst, and pure drinking water creation. These projects can then potentially produce carbon credits to reward both the issuers and retail investors, "Our then tokenized carbon credits will be for small players like farms and SMEs, and even the average person keen to contribute to helping Earth's environment."

09:21 EDT Mirum data published in Lancet shows benefits of Livmarli in PFIC - Mirum Pharmaceuticals announced that data from the Phase 3 MARCH-PFIC study evaluating LIVMARLI or maralixibat oral solution in patients with PFIC was published in The Lancet Gastroenterology and Hepatology. The MARCH-PFIC study was the largest, randomized, double-blind, placebo-controlled study in patients with PFIC, confirming the efficacy and safety of LIVMARLI, an IBAT inhibitor, across a broad genetic range of PFIC types. The main efficacy analyses were performed in two groups which included the BSEP deficiency cohort and the All-PFIC cohort which included patients with BSEP , FIC1 , MDR3 , TJP2 , or MYO5B deficiencies. The study met both the primary efficacy endpoint and the key secondary endpoint (mean change in total serum bile acid concentration between baseline and the average of weeks 18, 22, and 26 with statistically significant and clinically meaningful improvements observed by Week 2 and sustained throughout the 26-week study in LIVMARLI-treated participants in both the BSEP and All-PFIC cohorts. Improvements in bilirubin concentrations, growth, and sleep disturbances with LIVMARLI versus placebo were also observed. There were no new safety signals for LIVMARLI throughout the treatment periods with the most common adverse event being diarrhea, which was mostly mild and transient. The Phase 3 MARCH study presents the largest and most comprehensive dataset demonstrating the therapeutic benefit of an IBAT inhibitor across a broad range of PFIC types, including some which have not been previously studied. In addition to the clinical benefits observed, LIVMARLI significantly improved serum bile acids and bilirubin which are both known to be predictive of transplant-free survival. LIVMARLI represents a non-surgical, pharmacological option to improve outcomes for patients with PFIC.

09:19 EDT Safe and Green Development to acquire MyVonia - Safe and Green Development announces that it has entered into an agreement to acquire MyVONIA, an advanced artificial intelligence assistant, subject to certain closing conditions. Closing is expected during the second quarter of 2024. MyVONIA utilizes machine learning and natural language processing algorithms to provide users with human-like conversational interactions, tailored to their specific needs. David Villarreal, CEO of Safe and Green Development Corporation, expressed his excitement about the pending acquisition, stating, "We are thrilled to be acquiring MyVONIA and plan to integrate this advanced AI assistant into our operations. MyVONIA's cutting-edge technology is expected to not only provide valuable recurring revenue but to also enhance the user experience and streamline our processes. We expect that MyVONIA will eventually seamlessly integrate into our Xene AI Real Estate Platform allowing us to remain confident in our ability to stay at the forefront of innovation and offer unparalleled services to our clients."

09:17 EDT Sabre and Taiba sign strategic technology agreement - Sabre and Taiba Investments, a leading Saudi hospitality company with an extensive record in managing, developing, and operating hotels and residential compounds across the Kingdom of Saudi Arabia, announced the signing of a strategic technology agreement at the Arabian Travel Market event in Dubai. This collaboration will see the adoption of Sabre Hospitality's SynXis platform across multiple hotel brands within Taiba Investments' portfolio, including Makarem and Nur. . This partnership underscores both companies' commitment to leveraging innovative technology to drive growth and deliver exceptional guest experiences.

09:16 EDT Microchip announces new family of RT LE50-28 isolated DC-DC 50W power converters - The Low-Earth Orbit market is rapidly growing as private and public entities alike explore the new space region for everything from 5G communication and cube satellites to IoT applications. There is an increased demand for standard space grade solutions that are reliable, cost effective and configurable. To meet this market need, Microchip Technology announces a new family of Radiation-Tolerant LE50-28 isolated DC-DC 50W power converters available in nine variants with single- and triple-outputs ranging from 3.3V to 28V. The off-the-shelf LE50-28 family of power converters are designed to meet MIL-STD-461. The power converters have a companion EMI filter and offer customers ease of design to scale and customize by choosing one or three outputs based on the voltage range needed for the end application. This series provides flexibility to parallel up to four power converters to reach 200-Watts.

09:14 EDT Rush Street Interactive, Infront Bettor enter into strategic partnership - Infront Bettor and Rush Street Interactive have entered into a strategic partnership. The new agreement covers Infront's extensive portfolio, including access to the official fast path data of all International Tennis Federation events, exclusively distributed by Infront Bettor from 2025. Richard Schwartz, CEO Rush Street Interactive, said: "This partnership is a pivotal step for us in enhancing our offering to make sure we have premium and round-the-clock coverage for our customers. We are also very proud to continue to deliver the ITF to our bettors through next year, offering an enhanced tennis package that will see us consume more events than ever before. We know Infront has plans to offer a more immersive tennis betting experience, adding supplementary betting markets through collecting level 2 and level 3 data, and we look forward to seeing these come to life next year."

09:12 EDT Catheter Precision receives new purchase order, product evaluation at hospital - Catheter Precision announced the receipt of a purchase order for LockeT, the company's newest product, from the University of California San Diego health system. This initial purchase order from UCSD enables product evaluations at the hospital to begin.

09:12 EDT Crexendo selects Oracle Cloud Infrastructure to support growth - Crexendo announced availability of its hosted services globally on Oracle Cloud Infrastructure, marking a pivotal moment in Crexendo's rapid growth and geographic expansion. Working with OCI will help simplify Crexendo partners' business of operating a unified communications platform, and the security-first approach of OCI allows customers to not have to compromise between reliability, security, and cost. With more than 4.5 million users on Crexendo's NetSapiens platform, this move offers unparalleled flexibility, enabling partners to use the software platform according to their preferences, whether in their own cloud environment or within Oracle's secure cloud.

09:10 EDT Model N introduces new rebate enhancement - Model N has introduced a critical product enhancement that supports evolving compliance needs around the Inflation Reduction Act, IRA. The company has introduced a new Medicare Part D inflation rebate-per-unit, ensuring pharma manufacturers remain compliant with impending IRA regulation and avoid significant revenue loss. "The Inflation Reduction Act introduces sweeping changes for drug pricing and Medicare programs, and our goal is to empower customers to stay ahead of these shifts," said Suresh Kannan, Chief Product Officer at Model N. "As our life sciences customers prepare for new reforms and regulatory changes, Model N's latest product innovations address a critical market need by providing the capabilities necessary to calculate and process complex Medicare Part D inflation rebates."

09:10 EDT FSD Pharma submits Phase 1 MAD trial application for Lucid-21-302 - FSD Pharma announces the submission to ethics of a trial entitled "A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of Lucid-21-302 in Healthy Adult Participants." This clinical trial application is submitted for review by a human ethics review committee in Australia, a step that is necessary to obtain permission to initiate the multiple ascending dose trial. The MAD trial follows the Phase-1 single ascending dose trial that was recently completed. Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound with a unique mechanism of action for the treatment of multiple sclerosis. It is a patented New Chemical Entity that has been shown in preclinical models to prevent demyelination, a known cause of MS and other neurogenerative diseases characterized by damage to the myelin sheath surrounding nerve fibers in the central nervous system. In the prior Phase-1 single ascending dose study, Lucid-21-302 was shown to be safe and well-tolerated in the dose range of 50-300 mg administered once orally to healthy adults, with no difference in pharmacokinetics between the fed and fasted states.

09:10 EDT Nano Labs' CEO Jianping Kong increases his shareholding in the company - Nano Labs announced that Jianping Kong, the Company's chairman and CEO, informed the Company that he purchased 887,998 Class A ordinary shares of the Company in open-market transactions with his personal funds in April. Such transactions complied with the Company's internal trading policy as well as relevant laws and regulations. Kong is optimistic about the Company's future prospects in the long term and does not rule out the possibility of continuing to increase his shareholding in Nano Labs in the future.

09:09 EDT Dotdash Meredith announces strategic partnership with OpenAI - Dotdash Meredith announced a strategic partnership and licensing agreement with OpenAI that will enhance ChatGPT with DDM's trusted content, including time-tested recipes, expert health and financial information, leading style and entertainment content, and rigorous product reviews from America's most celebrated media brands. DDM brands include PEOPLE, Better Homes & Gardens, FOOD & WINE, Verywell, InStyle and Investopedia. As part of the agreement, OpenAI will display content and links attributed to DDM in relevant ChatGPT responses. OpenAI will also collaborate with DDM to create new AI products and features for its readers and use historical and ongoing DDM content to enhance its model's performance.

09:08 EDT Mob Entertainment signs deal with Scholastic - Mob Entertainment, a transmedia entertainment company, creators of the Poppy Playtime franchise and Huggy Wuggy, announced it has signed a deal with Scholastic Corporation, the global children's publishing, education and media company. Launching on May 7th, the "Poppy Playtime Orientation Notebook" promises an unforgettable journey into the enigmatic realm of Playtime and the origins of Huggy Wuggy, the Smiling Critters, and other favorite characters from the hit horror video game.

09:06 EDT Western Uranium & Vanadium provides shareholder update - Western Uranium & Vanadium offered the following update on uranium markets and Company operations. In response to Russia's war in Ukraine, the United States legislature passed the Prohibiting Russian Uranium Imports Act. We expect the President to sign this legislation into law shortly as the Biden administration has previously considered using an executive order to limit Russian uranium imports. The ban will go into effect 90 days after its enactment and will be phased in under Department of Energy conditional waivers before becoming a complete ban on January 1, 2028. Importantly, the enactment of a Russian ban releases funding to support the American nuclear supply chain. Energy Fuels has announced that it expects to offer an ore buying program. A uranium milling run is scheduled to begin in late 2024 or 2025 at their White Mesa Mill, the only operational conventional uranium/vanadium mill in the United States. Western and Energy Fuels have had initial discussions regarding the delivery of mined material from the Sunday Mine Complex. If a mutually beneficial arrangement can be established, Western could pivot its current mining operations to begin deliveries of uranium/vanadium mined material in as little as 30 days at annualized quantities up to 250,000 pounds of uranium and 1,000,000 pounds of vanadium. Western has entered into a joint venture with Rimrock Exploration and Development, a private company which owns two fully permitted, developed, and past producing uranium mines in Colorado. Western will fund mining operations and initially Rimrock will be the operator. Upon the payment of the full initial contribution, each party will own a 50% interest in the underlying mines and mining claims. Western has already funded more than half of the initial contribution. These mines access shallow uranium deposits where mined material is available at depths of 60 and 120 feet. The joint venture will sell the mined material to Western under terms to be determined. The mines do not have a technical report but are anticipated to provide marginal production to supplement Western's Sunday Mine Complex production. Western continues to ramp up operations to achieve its annualized production target of 1 million pounds of uranium and 6 million pounds of vanadium. Participation in the aforementioned buying program should not hinder the development of an adequate uranium feedstock supply for the Maverick Minerals Processing Plant. Precision Systems Engineering (is targeting to release the preliminary engineering design and cost estimate in June. At the beginning of 2024 Western expanded the Sunday Mine Complex mining operations by deploying two alternating mining crews and two alternating drilling teams who operate seven days a week. Following the expansion of infrastructure deeper into the West Sunday Mine, the mining teams commenced driving a drift approximately 2,700 feet to the Leonard & Clark deposit. So far, the teams have drifted approximately 317 feet and are now deploying a jumbo drill to increase progress. The drilling teams continue to define additional mining areas utilizing underground horizontal drilling. Between January 25th and March 31st, the team has drilled a total of 8,170 linear feet with 43 long hole drill targets at three separate areas of the GMG deposit.

09:06 EDT Johnson Controls appoints Chris Bontempo as Chief Marketing Officer - Johnson Controls announced it has appointed Chris Bontempo as vice president and chief marketing officer, responsible for marketing strategies across the enterprise to drive demand generation and enhance brand equity, including market development, research and planning. Bontempo joins Johnson Controls from IBM where he spent nearly 20 years in roles of increasing responsibility, most recently as chief marketing & communications officer, Americas. In that capacity, he led all aspects of marketing for IBM across the United States, Canada and Latin America, with direct responsibility for marketing-sourced revenue, demand generation and marketing teams. Bontempo will report to Chairman and CEO George Oliver and serve on the Johnson Controls executive team, working closely across corporate businesses and functions to grow market share in products, systems and services. Bontempo holds a Master of Business Administration from Columbia Business School and a Bachelor of Arts degree in European Studies from Amherst College.

09:04 EDT ALX Oncology appoints Dillon as Chief Business Officer - ALX Oncology (ALXO) announced the appointment of Allison Dillon, Ph.D., as Chief Business Officer, CBO. Dr. Dillon joined ALX Oncology from Calithera Biosciences (CALA), where she most recently served as Senior Vice President of Commercial and Portfolio Strategy until 2023.

09:02 EDT Veeco announces semiconductor company placed order for laser annealing systems - Veeco Instruments announced that a semiconductor company has placed an order for multiple laser annealing systems to accelerate the design and manufacturing of 2-nanometer gate-all-around logic semiconductor chips. The order includes LSA201 Laser Spike Annealing Systems in addition to an NSA500 Nanosecond Annealing System. Gate-all-around is a vertical stacking of planar channels resulting in improved device drive current capability with minimal leakage, less power consumption, and overall enhanced performance. "We are excited to have our annealing platforms chosen to accelerate next-generation gate-all-around logic device production to meet demand for growing markets such as artificial intelligence," commented Adrian Devasahayam, Ph.D., Veeco's Senior Vice President, Product Line Management. "Veeco's LSA system is widely acknowledged as the optimum annealing solution for low thermal-budget applications in logic. The new NSA500 system offers customers superior performance, scalability, and productivity to enable product roadmaps. These benefits are essential to ensuring high device performance as node sizes decrease and production complexity increases."

09:02 EDT Standex sees slightly to moderately higher revenue in Q4 - The company states: "In the fiscal fourth quarter 2024, on a sequential basis, the Company expects slightly to moderately higher revenue due to favorable project timing in the Engineering Technologies segment, increased market demand in the Specialty Solutions segment, and the impact of the Company's recent acquisition of Sanyu. The Company expects slightly to moderately higher adjusted operating margin sequentially due to leverage on higher sales and pricing and productivity actions."

08:58 EDT Moleculin Biotech reports interim data for Annamycin - Moleculin Biotech announced the presentation of positive interim data for Annamycin from its ongoing acute myeloid leukemia, or AML, clinical development program. As previously announced, the Company will host a virtual AML Clinical Day to discuss these results. "Adding the latest two subjects in MB-106 AML trial with AnnAraC brings the composite complete remission, or CRc, rate up from 37% to 45% for all of the 20 subjects with prior therapies ranging from none to six. This adds to our growing body of positive data which continues to provide a clear line of sight for our clinical and regulatory strategies towards registration for Annamycin in AML," commented Walter Klemp, Chairman and CEO of Moleculin. "Focusing on 2nd line subjects, a CRc rate of 60% and with 50% of those being full CRs, AnnAraC has the potential to offer 2nd line patients a viable alternative, regardless of prior treatments or mutations. While we believe that the full trial results are impressive, we continue to believe that our results in 2nd line subjects, where there is a significant unmet need, are exceptional and believe the CRc rate demonstrated by AnnAraC in 2nd line patients substantially exceeds the performance reported by any drug currently approved for use in 2nd line AML. The Company is currently conducting its Phase 1B/2 clinical trial evaluating Annamycin in combination with Cytarabine for the treatment of subjects with AML as both first line therapy and for subjects who are refractory to or relapsed after induction therapy. To date, 20 subjects have been enrolled in the full MB-106 Phase 1B/2 study. The median durability of remission is 4.9 months and climbing. DoR is defined as the time from initiation of treatment to the point of disease relapse or death. At the end of January 2024, the Company completed recruiting the desired number of 2nd line subjects and began preparation for an End of Phase 2 meeting with the FDA.

08:56 EDT ECD Automotive Design electrifies classic Mustangs - ECD Auto Design announces the integration of cutting-edge EV powertrains into its Mustang Fastback and Convertible models. Following the recent announcement of ECD Auto Design's product expansion into the American muscle car market, this significant move emphasizes the company's commitment to innovation, sustainability and ultimately customization options.Built upon ECD's legacy of precision and excellence, the classic Ford Mustang line will now offer electric powertrain options, crafted within ECD's state-of-the-art 100,000 square foot facility. Each vehicle will exemplify ECD's dedication to pushing the boundaries of automotive design. In line with ECD's world renown customization model, every classic Mustang will offer a range of powertrain configurations, allowing customers to tailor their vehicles to their preferences. The electric powertrains will be based off ECD's second generation 300 HP with direct drive units and will include DC fast charging. Twin Derale high performance coolers are utilized for optimal flexibility and airflow. The range for the Mustang EV model is approximately 150 miles, fully charged.

08:50 EDT Presto Automation announces launch of Presto Voice with Pure AI - Presto Automation announced the launch of Presto Voice with Pure AI, a transformative feature that delivers enhanced Voice AI order taking for restaurants. "Presto Voice Pure AI represents a major leap forward in restaurant automation technology, providing operators with a Voice AI-powered solution to deliver an efficient drive-thru ordering experience to their guests," said Gee Lefevre, Interim CEO at Presto.

08:48 EDT IMAC Holdings acquires assets of Theralink - On May 1, 2024, as previously announced, pursuant to that certain Settlement and Release Agreement, by and between IMAC Holdings and Theralink Technologies, BACK acquired the assets of Theralink, other than certain excluded assets, in settlement of the default by Theralink of certain outstanding debt and BACK's agreement to issue certain shares of preferred stock of BACK to Theralink and/or certain holders of debt of Theralink, as applicable, in the future following the completion of a third party valuation of Theralink's business. With BACK already in possession of such assets of Theralink, and a merger with Theralink no longer necessary to acquire such assets, on May 6, 2024, BACK, IMAC Merger Sub and Theralink entered into a Termination Agreement, which immediately terminated the Agreement and Plan of Merger, dated May 26, 2023, by and between BACK, Merger Sub and Theralink. BACK is formally withdrawing the corresponding Registration Statement on Form S-4, in connection with such termination of the Merger Agreement.

08:48 EDT Bitdeer mined 265 bitcoin in April - Bitdeer Technologies Group announced its unaudited mining and operations updates for April 2024. Linghui Kong, Chief Business Officer of Bitdeer, commented, "The month of April marked a period of stable operations for our company as we made steady progress towards our long-term development goals. We mined 265 Bitcoins in total during April, representing an increase of 13.7% from the same period last year and a decline of 9.9% from March 2024. This month-over-month decline was related to the impact of the latest Bitcoin halving event, which occurred on April 19, 2024. Our Gedu datacenter maintained stable operations throughout the month of April, thanks in large part to our power pricing agreement for the site, which has allowed us to operate the site with lower costs and without the need to curtail datacenter activity.

08:47 EDT Peloton jumps 18% to $4.19 after CNBC says private equity weighing buyout

08:46 EDT ImmunityBio finishes GMP drug substance manufacturing for 170K Anktiva doses - ImmunityBio announced that the drug substance DS has been completed and successfully qualified for "fill finish" , sufficient for 170,000 doses of 400mcg ANKTIVA ... Coupled with the recent announcement of a partnership with the Serum Institute of India (SII) for BCG availability, this provides the Company with a significant initial supply of ANKTIVA for commercial and clinical trial use in advance of the full operation of the Company's own drug substance and fill-finish manufacturing plants in California and New York...Since the Company's merger with NantKwest in 2021, ImmunityBio has made significant capital investments in personnel, plants, and equipment to ensure global capacity of ANKTIVA drug product for both the commercial launch, as well as clinical trials in bladder cancer and other tumor types in its pipeline. Both drug substance DS and drug product DP facilities are nearing completion to ensure sufficient capacity and multiple GMP manufacturing sites for ANKTIVA in its approved indication, as well as for clinical trials and future indications.

08:45 EDT Synovus sees CET1 ratio increase of 40-50bps from risk weighted asset reduction - In a regulatory filing yesterday, the company stated: "On May 6, 2024, Synovus substantially completed a risk weighted asset ("RWA") optimization analysis of certain of its loan portfolios to determine eligibility for reduced risk weighting. This analysis included such segments as securitization finance, multi-family mortgage, government lending, and residential mortgage. Based on this analysis, Synovus now expects an incremental reduction in RWA in the second quarter of 2024 of approximately $2.0 to $2.4 billion which will result in a marginal increase in its common equity tier 1, or "CET1", ratio of approximately 40 to 50 basis points. Absent the planned actions noted below, Synovus would expect its CET1 ratio to exceed the previously announced targeted range of 10.0% to 10.5%. The increase in capital ratios resulting from this RWA optimization provides flexibility for incremental capital deployment and as such, Synovus expects, subject to market conditions, to reposition a portion of its $11 billion securities portfolio throughout the month of May. As part of this exercise, Synovus anticipates selling available-for-sale securities with a book value of approximately $1.6 billion, resulting in a pre-tax loss of approximately $275 million, with funds redeployed into other high quality liquid assets. Synovus expects this transaction to positively impact its future net interest income and net interest margin profile, with an estimated earn back period of approximately five years. After the foregoing anticipated securities repositioning, Synovus will continue to operate at the upper end of its targeted range of a 10.0% to 10.5% CET1 ratio."

08:44 EDT Ainos raises $9M in growth capital with existing shareholder - Ainos sold a $9 million convertible note with a conversion price of $4.50 to an existing shareholder. The note bears 6% compound interest rate and is convertible into the Company's common shares at $4.50, and warrant coverage is 500,000 shares, with a strike price of $4.50 and five years to expiration. Ainos has several programs under development for which the growth capital can be used. For its AI Nose platform, Ainos aims to advance its flagship VOC POCT candidate Ainos Flora. Ainos has initiated the second phase of collaboration with Nisshinbo Micro Devices and Taiwan Inabata Sangyo for an AI Nose-powered VOC sensing platform with potential applications spanning a wide variety of industries, including telehealth, automotive, industrial, and environmental safety. VELDONA investigational new drugs are also a key program with the potential to deliver high-quality, safe, and effective therapeutics for a variety of indications. This growth capital will be pivotal in propelling Ainos forward in advancing clinical studies and the Company's active pursuit of out-licensing of VELDONA human drug candidates, including its candidate for treating oral warts in HIV-seropositive patients.

08:43 EDT OSI Systems receives $6M order to provide electronic assemblies - OSI Systems announced that its Optoelectronics and Manufacturing division has received an order for approximately $6M to provide electronic assemblies to an advanced engineered solutions OEM.

08:42 EDT Alliance Entertainment announces results of Record Store Day events - Alliance Entertainment announced results of last month's Record Store Day events. Record Store Day is an annual event inaugurated in 2007 and held on one Saturday every April to "celebrate the culture of the independently owned record store'" and brings together fans, artists, and thousands of independent record stores around the world. As in past years, artists and record labels produce vinyl content pressed exclusively for Record Store Day. These exclusives are distributed to more than 1,500 record stores in the US participating in the event. Now in its 17th year, and haven taken place this year on April 20, 2024, the Record Store Day phenomenon continues to grow. Many attribute the success of Record Store Day to the continued growth and expansion of vinyl records across the music industry with physical vinyl album sales in 2023 surpassing 43 million units.

08:42 EDT Sealsq, The Hashgraph Association launch new digital asset - SEALSQ announced that in partnership with The Hashgraph Association have launched a new digital asset built on Hedera Network that caters to the Decentralized Physical Infrastructure Network sector, by enabling billions of internet connected devices to autonomously engage in seamless data and currency exchanges. Under the umbrella of Transactional Internet of Things, TIoT, SEALCOIN is a hybrid payment and utility token for enabling billions of internet-connected devices to autonomously engage in seamless data and digital asset exchanges. A significant milestone is being reached with the release of a M2M Proof of Concept enabling the disintermediation of service providers for interconnected devices. The release is scheduled for mid-July 2024, with a comprehensive demo planned shortly thereafter, showcasing the innovative capabilities of SEALCOIN in enabling Service vs Payment transactions between machines. SEALCOIN is expected to launch in Q4 2024 and will then be listed on a digital asset exchange.

08:40 EDT Barfresh Food Group adds new customers in the education channel - Barfresh Food Group reinforced its education channel sales momentum today by announcing new multi-state customer wins, broadening its reach in this key market. The Company recently secured 443 new school locations, representing a collective population of over 360,000 students. These new school locations plan to introduce a varied selection of the Company's products, including its Twist & Go carton and bottled smoothie products, 5:1 100% juice concentrates and 1:1 bulk easy pour smoothie concentrates to their students starting in fall 2024 for the 2024-2025 school year. Over the past two weeks, Barfresh has announced over 2,600 new customer school locations, representing close to two million students, that will be served a range of the Company's products either on their breakfast menus or a la carte menus. With numerous bids in the education channel currently underway, the Company anticipates announcing a significant number of new customer wins before the 2024-2025 school year commences.

08:39 EDT NRSInsights says April same-store sales increased 2.5% - NRSInsights announced comparative same-store sales results for April 2024. As of April 30, 2024, the NRS retail network comprised approximately 30,300 active terminals scanning purchases at independent retailers including bodegas, convenience stores, liquor stores, grocers, tobacco, and sundries sellers nationwide, predominantly serving urban consumers. April Retail Same-Store Sales Highlights: Same-store sales increased 2.5% from a year earlier. In the previous month, average sales increased 7.2% compared to March 2023. Same-store sales decreased 0.9% compared to the previous month. Same-store sales in March 2024 increased 6.6% compared to the previous month. For the three months ended April 30, 2024, same-store sales increased 3.8% compared to the three months ended April 30, 2023. The number of items sold increased 3.7% from a year earlier. In the previous month, the number of items sold increased 7.8% compared to March 2023. The average number of transactions per store increased 1.7% from a year earlier. In the previous month, the average number of transactions increased 4.6% compared to March 2023. A dollar-weighted average of prices for the top 500 items purchased increased 0.2% year-over-year, a decrease from the 0.7% year-over-year increase recorded in March 2024.

08:38 EDT Scansource announces $100M share repurchase program - ScanSource announced a new $100M authorization by its board of directors to purchase shares of the company's common stock. This supplements the existing authorization of which approximately $45M remained outstanding as of March 31.

08:37 EDT KULR Technology completes 200 amp-hour battery test for EV customer - KULR Technology announced the Company has successfully completed large format fractional thermal runaway calorimeter tests for 200 Amp-hour high energy Nickel Manganese Cobalt prismatic format lithium-ion cells for its global automotive OEM customer. As the exclusive licensee of the L-FTRC technology from NASA, KULR is uniquely positioned to service customers in electric vehicles, grid energy storage and industrial applications with L-FTRC testing of their batteries in the global cell testing market estimated to reach USD $7 billion by 2030. Just last year, a leading global automaker selected KULR for its next-generation EV battery safety and testing solutions. Recently, EV automakers have been exploring high-performance silicon-anode batteries and other technologies to enhance driving range and reduce costs in future electric vehicles. The S-FTRC, a NASA Invention of the Year Award Winner, was expanded in 2018 to accommodate large format cells. This technology was eventually licensed by KULR Technology Corporation on an exclusive basis in 2023. With this technique, KULR can characterize total energy yield, fractional energy yield, and mass ejection distributions for the largest of lithium-ion cell formats available. This arrangement also allows KULR to extract and submit gas samples for third party gas speciation analysis.

08:36 EDT IceCure Medical announces data from independent study on ProSense - IceCure Medical announced that positive data from an independent study performed in Japan was published in an article titled "Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan," in the journal Breast Cancer on April 27. The Study, which focused on the local control of cancer, safety, patient quality of life, patient satisfaction, and cosmetic outcomes of cryoablation for patients with early-stage breast cancer, is the continuation of a prior pilot study that demonstrated percutaneous cryoablation treated with ProSense is a potential standard treatment for early-stage breast cancer patients, given compliance to pre-defined patient selection criteria. Terumo Corporation owns the exclusive distribution rights for ProSense in Japan for a 5-year term following regulatory approval. In exchange for exclusive distribution rights, IceCure is expected to receive a total of $13.2M in proceeds from Terumo during this initial term, of which it has received $4M to date, with an additional $8.2M expected upon the completion of orders, as well as $1M expected for milestone-based payments.

08:35 EDT Inozyme expects cash to fund operations into Q4 of 2025 - Cash, cash equivalents, and short-term investments were $166.2 million as of March 31, 2024. Based on its current plans, the Company anticipates its cash, cash equivalents, and short-term investments as of March 31, 2024, will enable the Company to fund cash flow requirements into Q4 2025.

08:35 EDT Be A Part Of partners with Bridgeline's HawkSearch - Bridgeline Digital announces its strategic partnership with Be A Part Of. This collaboration between Bridgeline's site search product, HawkSearch, and Be a Part Of signals a significant advancement in revolutionizing ecommerce search experiences for brands worldwide. Be A Part Of leverages HawkSearch's capabilities in ecommerce search, product discovery, and recommendations to enhance online shopping journeys for its client roster of global brands, wholesalers, and retailers. By integrating HawkSearch's technology, Be A Part Of aims to empower brands to elevate engagement, drive conversions, and maximize revenue across their digital platforms.

08:33 EDT Real Brands appoints Richard Goldberg to board of directors - Real Brands Inc. has added Richard J. Goldberg, MD, MS, to its Board of Directors, and The Company has entered into a consulting agreement with Dr. Goldberg for guidance and expertise in Real Brand's new Psychedelics research division that was launched in 2023. Goldberg has been appointed to the highest levels in Psychiatry at premier academic and healthcare institutions, has served on the editorial boards and review committees for the top peer-reviewed Psychiatry medical journals, served on dozens of advisory boards and committees, has founded and led successful healthcare corporations, and has had scores of papers published in peer-reviewed medical journals.

08:29 EDT Mynaric selected by Rocket Lab for SDA's Tranche 2 Transport Layer - Mynaric (MYNA) has been selected by Rocket Lab USA, Inc (RKLB) to supply free space optical terminals for the Space Development Agency's Tranche 2 Transport Layer - Beta program. Rocket Lab was awarded the 18-vehicle program in January 2024. The order of CONDOR Mk3 terminals is valued at approximately $15 million with deliveries beginning in 2025 and continuing into 2026.

08:27 EDT Wex in deal with Shell to manage portfolio of commercial fleet cards in N.A. - WEX announced that it has reached an agreement with Shell to manage Shell's portfolio of commercial fleet cards across North America, offering customers a full range of features, functionality, and solutions to meet the everyday demands of a modern commercial fleet. This represents a continuation of agreements first established in 2018 and covers the United States, Canada, and Mexico. "With more than 19.4 million commercial vehicles serviced globally, customers and partners rely on WEX's software and payments solutions to simplify the fleet management process," said Melissa Smith, WEX's Chair, Chief Executive Officer, and President. "WEX's technological expertise in fleet mobility combines with Shell's significant brand presence across North America to provide an operational advantage for enterprise-level fleet operators and small business fleets alike. This agreement illustrates the power of WEX's global commerce platform and our continued commitment to simplifying the business of running a business." Inclusive of cobranded offerings with Shell, WEX is a leader in commercial mobility solutions with more than 600,000 businesses as customers within its Mobility segment, representing approximately 19.4 million commercial vehicles serviced globally as of Q1 2024. Both WEX and Shell were recognized in a Forbes ranking of Best Fleet Fuel Card Providers.

08:25 EDT Mainz Biomed to present results of colorectal cancer study at DDW 2024 - Mainz Biome will present an analysis from its eAArly DETECT study at Digestive Disease Week, DDW, 2024 in Washington D.C. from May 18th to May 21st. DDW is recognized as a premier forum for the latest advancements in gastroenterology, hepatology, endoscopy, and gastrointestinal surgery. eAArly DETECT is a US multi-site study performed at 21 specialized gastroenterology sites that enrolled 254 clinical patients. The results show performance of its multimodal screening test combining Fecal Immunochemical Test, DNA and mRNA biomarkers with a unique artificial intelligence / machine learning algorithm to differentiate between colorectal cancer, advanced adenomas, non-advanced adenomas and patient samples with no findings.

08:22 EDT Traws Pharma announces first cohort dosed in Phase 1 trial of COVID therapy - Traws Pharma announced that it completed dosing in the first cohort of the first-in-human Phase 1 study to evaluate travatrelvir, an orally-available protease inhibitor, in development for treatment of COVID19. There have been no safety observations reported. "COVID-19 remains a significant global health concern, with SARS-CoV-2 infections posing a leading cause of mortality, especially among individuals aged 65 and above," stated Werner Cautreels, Ph.D., Chief Executive Officer of Traws Pharma. "Subject to future study results, we believe that travatrelvir may represent a major potential advance in the treatment of SARS-CoV-2 and are thrilled to advance this program into the first human clinical studies. We expect to report topline data from the Phase 1 study in H2 2024, followed by the initiation of an international Phase 2 safety and efficacy study."

08:21 EDT Integer to showcase strategic investments at Heart Rhythm 2024 - Integer Holdings will join medtech industry leaders around the world in exhibiting at Heart Rhythm 2024, a Heart Rhythm Society educational event and exhibition in Boston from May 16 - 19, 2024. HRS attendees are invited to visit Integer at booth #753 to learn more about the company's comprehensive end-to-end solutions, designed to help customers accelerate time to market, strengthen innovation, simplify supply chain and confidently scale production across a globally competitive network of locations. Some examples include market-leading battery technology, finished leads and implantable pulse generators for cardiac applications. Integer is a leading manufacturer of access and complex catheter access solutions in electrophysiology, including guidewires, transseptal access, diagnostic and ablation technology platforms. Those attending HRS will discover how Integer's recent strategic investments, particularly the acquisition of Pulse Technologies, are reshaping how Integer serves the world's leading medical device OEMs and start-ups. Pulse Technologies, based in Quakertown, Pennsylvania, brings unmatched precision machining and patented technologies such as Hierarchical Surface Restructuring coatings to Integer's portfolio. These innovations significantly enhance the performance and reliability of medical devices across cardiac rhythm management, neuromodulation, and cardiovascular applications. HSR enhances electrodes and microelectrode arrays using a proprietary ultra-short pulse laser-based process, supporting a range of applications.

08:20 EDT Oragenics partners with Avance Clinical for Phase II concussion trial - Oragenics announced a partnership with Avance Clinical, a leading Contract Research Organization, CRO, to conduct a Phase II clinical trial in Australia. This trial aims to evaluate Oragenics' lead drug candidate, ONP-002, for mild Traumatic Brain Injury, TBI, commonly known as concussion. ONP-002, a novel chemical entity, NCE, is delivered through a unique intranasal device and designed to maximize drug delivery directly to the brain. Michael Redmond, President of Oragenics, added, "Our collaboration with Avance Clinical during the Phase I trial was instrumental, and we are confident in their ability to execute an effective Phase II trial that will pave the way for future treatment protocols for concussion."

08:18 EDT Whitestone REIT issues letter to shareholders on upcoming election - Whitestone REIT issued a shareholder letter from independent Board Chair David Taylor and Chair of the Nominating and Corporate Governance Committee, Nandita Berry. In their joint letter, Berry and Taylor detail the challenging and decisive actions they took as change agents to terminate the former CEO James Mastandrea for cause, revitalize corporate governance, and oversee the successful ongoing value creation plan under the new management team executing on Whitestone's reset strategy. Berry, Taylor and the entire Board at Whitestone request that shareholders protect their investment by voting the WHITE proxy card "FOR ALL" of Whitestone's trustees standing for election at the upcoming Annual Meeting scheduled to be held on May 14, 2024.

08:18 EDT Power Integrations to acquire Odyssey Semiconductor Technologies - Power Integrations announced an agreement to acquire the assets of Odyssey Semiconductor Technologies, a developer of vertical gallium-nitride transistor technology. The transaction is expected to close in July, after which all key Odyssey employees are expected to join Power Integrations' technology organization. The acquisition supports the company's ongoing development roadmap for its proprietary PowiGaN technology, which is featured in many of the company's product families including InnoSwitch ICs, HiperPFS-5 power-factor-correction ICs and the recently launched InnoMux-2 family of single-stage, multiple-output ICs. The company introduced 900- and 1250-volt versions of PowiGaN technology and products in 2023.

08:16 EDT Eterna to present on development of B2M-KO iMSC line at ASGCT meeting - Eterna Therapeutics announces that Raven Hinkel will present at the 27th Annual Meeting of the American Society of Gene & Cell Therapy, taking place in Baltimore, Maryland. While mesenchymal stem cells have repeatedly demonstrated significant therapeutic potential in numerous preclinical models, their clinical translation has been greatly impeded by variability in therapeutic responses. This variability is often attributed to donor and source heterogeneity and limited expansion potential. Furthermore, MSCs can exhibit limited in vivo persistence due to clearance by host immune cells, which can also contribute to deficient therapeutic responses. Induced pluripotent stem cell-derived MSCs promise to directly address many of the fundamental challenges facing MSC translation. Here, we report the development of a beta 2 microglobulin-knockout iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs in treating inflammatory diseases by precluding batch-to-batch inconsistencies, promoting in vivo persistence, and enhancing the effector function of the cells. The abstract concludes that B2M-KO iMSCs are more likely to evade immune clearance and exert their immunomodulatory effects, as demonstrated by their enhanced sensitivity of IDO1 expression and their improved ability to inhibit PBMC proliferation. Our data suggest that B2M-KO iMSCs may be a promising therapeutic agent for T-cell mediated autoimmune and inflammatory indications.

08:15 EDT Silynxcom, 3M PELTOR further collaborate on ComTac VII Headset - Silynxcom announced the expansion of its ongoing collaboration with 3M PELTOR. Peltor and Silynxcom have agreed to expand their mutual convertion distributor agreement to include Peltor's latest innovative product - the Peltor ComTac VIII Headset. The ComTac VIII Headset offers improved sound protection, hardware design and user application. The ComTac VIII Headset represents the pinnacle of Peltor's engineering excellence. Engineered for both communication and protection, the ComTac VIII Headset features advanced technology to enhance auditory situational awareness in noise-intense environments.

08:14 EDT Disney 'on track' for over $8B in free cash flow in FY24 - The company stated, "In the second fiscal quarter of 2024, we achieved strong double digit percentage growth in adjusted EPS, and met or exceeded our financial guidance for the quarter. As a result of outperformance in the second quarter, our new full year adjusted EPS growth target is now 25%. We remain on track to generate approximately $14 billion of cash provided by operations and over $8 billion of free cash flow this fiscal year. We repurchased $1 billion worth of shares in the second quarter and look forward to continuing to return capital to shareholders. The Entertainment Direct-to-Consumer business was profitable in the second quarter. While we are expecting softer Entertainment DTC results in Q3 to be driven by Disney+ Hotstar, we continue to expect our combined streaming businesses to be profitable in the fourth quarter, and to be a meaningful future growth driver for the company, with further improvements in profitability in fiscal 2025. Disney+ Core subscribers increased by more than 6 million in the second quarter, and Disney+ Core ARPU increased sequentially by 44 cents. Sports operating income declined slightly versus the prior year, reflecting the timing impact of College Football Playoff games at ESPN, offset by improved results at Star India. The Experiences business was also a growth driver in the second quarter, with revenue growth of 10%, segment operating income growth of 12%, and margin expansion of 60 basis points versus the prior year. Although the third quarter's segment operating income is expected to come in roughly comparable to the prior year, we continue to expect robust operating income growth at Experiences for the full year."

08:13 EDT JetBlue, Etihad Airways announce addition of loyalty benefits - JetBlue and Etihad Airways announced the addition of loyalty benefits starting May 8 as part of its long-standing codeshare partnership. The agreement between the two airlines was celebrated at Dubai's Arabian Travel Market. As part of the partnership, members of JetBlue's TrueBlue loyalty program and members of Etihad Guest, the loyalty program of Etihad Airways, will now be able to earn and redeem points in the program of their choice when flying across the network of either airline.

08:11 EDT MoonLake Immunotherapeutics announces anticipated events - Important upcoming anticipated events for MoonLake: Q2-2024: Initiation of the Phase 3 VELA program in HS; Q2-2024: End-of-Phase 2 meetings with the FDA and EMA for PsA; 2H-2024: Initiation of the Phase 3 program in PsA; 2H-2024: Initiation of additional studies as announced for dermatology and rheumatology indications

08:05 EDT PayPal names Steve Winoker as Chief Investor Relations Officer - PayPal Holdings (PYPL) announced that Steve Winoker has been named Chief Investor Relations Officer, effective May 15. Winoker will report to Jamie Miller, CFO, and be responsible for communicating the vision and progress of PayPal's transformation to the financial community. Winoker joins PayPal from GE, where he most recently served as Chief Investor Relations Officer and Group Vice President for GE Aerospace (GE).

08:02 EDT Bowlero says will be near low end of FY24 guidance - In the company's Q3 earnings announcement yesterday, Bowlero stated: "After completing three fiscal quarters, we now expect to be near the low end of our fiscal year 2024 Revenue and Adjusted EBITDA guidance."

07:49 EDT Clearmind Medicine enters licensing agreement with Yissum Research - Clearmind Medicine announces the signing of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. This agreement provides Clearmind with exclusive global rights to further develop, manufacture, and commercialize innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa and Avi Priel from the Hebrew University. These novel compounds are targeted at treating post-traumatic stress disorder and other mental health conditions. Under the terms of the agreement, Clearmind receives exclusive rights to develop, manufacture, and commercialize novel compounds for treating PTSD and other mental health disorders. Clearmind is responsible for the ongoing development and potential commercialization in line with regulatory guidelines.The agreement includes future milestone payments, royalties on future sales, and commitments to safeguard intellectual property rights.

07:45 EDT Invivyd to submit EUA to FDA for treatment of mild to moderate COVID-19 - Invivyd announced its intention to submit an emergency use authorization, EUA, application to the U.S. Food and Drug Administration, FDA, for pemivibart for the treatment of mild to moderate symptomatic COVID-19 in certain immunocompromised people utilizing a rapid immunobridging pathway. This immunobridging pathway leverages a similar approach Invivyd used to achieve its current EUA for PEMGARDA for pre-exposure prophylaxis of COVID-19 in certain immunocompromised people and was aligned in principle with the FDA. The immunobridging pathway for COVID-19 treatment is enabled by data from the Phase 2/3 clinical trial of adintrevimab, the prototype monoclonal antibody, for the treatment of COVID-191 and data from the ongoing CANOPY Phase 3 clinical trial of pemivibart for PrEP of COVID-19. The potential COVID-19 treatment EUA request would focus on the critical treatment needs of people in the U.S. who have moderate-to-severe immune compromise and for whom alternative COVID-19 treatment options are not clinically appropriate or accessible. Subsequent to the anticipated submission of an EUA request, Invivyd plans to initiate a compact clinical trial focused on confirmatory safety, pharmacokinetics, and clinical virology.

07:44 EDT Amesite enters 5-year partnership with Fanciscan Missionaries of Our Lady Uni - Amesite announces a five-year partnership with Franciscan Missionaries of Our Lady University, Uni, to deliver healthcare training programs for working healthcare professionals in subjects ranging from leadership and management, quality improvement, healthcare finance, nursing continuing education, physical therapy continuing education, ethics in medicine and continuing medical education. Dr. Ann Marie Sastry, CEO of Amesite, Inc., commented, "Healthcare is a sector with deep and broad needs in professional certification and upskilling and partnering with colleges continues to be a way for us to meet market needs across the country. Amesite is committed to supporting our growing number of customers as we expand professional educational programs, driving revenue and impact."

07:43 EDT Thoughtworks CEO Guo Xiao to step down, Mike Sutcliff to succeed - Thoughtworks (TWKS) announced that Guo Xiao is stepping down from the role of CEO and director. The board of directors has selected Mike Sutcliff to succeed Guo Xiao as CEO and director. The changes will be effective June 17 and Guo Xiao will remain as an advisor to Thoughtworks to support the transition. Sutcliff brings extensive experience in technology, building and scaling businesses, driving growth and pioneering the evolution of Accenture Digital in his 32-plus year career at Accenture (ACN).

07:42 EDT Canopy Growth confirms acquisition of Wana and Jetty - Canopy Growth confirmed that Canopy USA has exercised the options to acquire Wana and Jetty. The exercise of these options is a critical next step to enable Canopy USA to fulfill its intent to establish a leading, brand-focused powerhouse. It is also expected that once completed, these acquisitions will enable Canopy USA to realize compelling financial benefits, including the ability to drive revenue growth, and realize cost synergies across the Canopy USA ecosystem. There is no additional consideration to be paid by Canopy USA for the exercise of the options to acquire each of: Wana, a leading cannabis edibles brand in North America and is vertically integrated in Colorado in addition to having a rapidly growing licensing division across 15 additional U.S. states and territories. Jetty, a California-based producer of high-quality cannabis extracts and pioneer of clean vape technology. Jetty pioneers the latest technology to create industry-leading extracts including award-winning solventless vapes, live resin vapes, and other products. The brand's products are available in California, Colorado, New York and New Jersey, and according to market research firm BDSA, Jetty Solventless vapes ranked as the #1 National Live Rosin vape brand2. Supported by nine years of operations, Jetty continues to define the vape category and is primed to further scale its high-quality products nationally. The closing of the acquisition of each of Wana Wellness, The CIMA Group, and Mountain High Products, collectively, "Wana", and Lemurian is subject to certain customary closing conditions, including receipt of regulatory approvals.

07:40 EDT Thoughtworks provides update on restructuring activities - The company said, "On August 8, 2023, Thoughtworks initiated several measures to reduce operational costs and better align our business with our customers' needs in a challenging macroeconomic environment. During the first quarter of 2024, Thoughtworks incurred pre-tax cash charges of approximately $2.1 million, which include $1.0 million in wage-related costs and $1.1 million in non-wage related costs. Since the program's inception in August 2023 through March 31, 2024, we have incurred pre-tax cash charges of approximately $21.1 million, which include $18.3 million in wage-related costs and $2.8 million in non-wage related costs, and have achieved $87 million of annualized savings, which is above our targeted range of $75 million to $85 million. We are continuing to execute on our plan, and we remain focused on driving additional savings. As we have undergone the process of improving our cost profile, we have identified additional opportunities to drive further cost savings. As a result, Thoughtworks is increasing its restructuring program to capture additional savings of $25 million to $30 million, for a total restructuring program savings of $100 million to $115 million. We still expect the restructuring program to be completed by the end of the third quarter of 2024. Thoughtworks expects to incur additional pre-tax cash charges of approximately $6.5 million to $8.0 million, for total expected pre-tax charges of approximately $26.5 million to $33.0 million (the "Updated Total Charges"). The Updated Total Charges include $22.5 million to $27.5 million in wage-related expenses, such as employee severance and related benefits, and $4.0 million to $5.5 million in non-wage related expenses, including costs related to reducing leased office space, vendor contract cancellations and professional fees."

07:40 EDT EVgo CFO Olga Shevorenkova resigns effective May 31 -

07:39 EDT Caledonia Mining announces results of Annual General Meetig - Caledonia Mining Corporation announces the results of its annual general meeting of shareholders held at St Helier, Jersey today. The total number of shareholders present in person or by proxy at the AGM was 96, representing 62.28% of the Company's outstanding voting shares. Proxy votes received on resolutions 1(a) to 1(h), which were duly passed by a show of hands, to reappoint the eight nominees proposed for re-election as directors. Further resolutions 2 and 3 were also passed at the AGM so that: BDO South Africa Inc was reappointed as the auditor of the Company for the ensuing year and the directors were authorised to approve their remuneration; and Mr. Holtzhausen, Mr. Wylie, Ms. Wildschutt and Ms. Gadzikwa were reappointed as members of the Audit Committee.

07:37 EDT Boots Capital sends letter to Crown Castle shareholders - Boots Capital Management, an investment vehicle led by Ted Miller, co-founder and former CEO of Crown Castle, sent a letter to Crown Castle shareholders in connection with the company's upcoming Annual Meeting scheduled for May 22nd, 2024. Reference Link

07:35 EDT Spirit AeroSystems not providing FY24 guidance - Spirit (SPR) will not be providing guidance until there is further clarity on the acquisition discussions with Boeing (BA), 737 MAX delivery and production timing, as well as ongoing commercial negotiations with Airbus (EADSY).

07:28 EDT Gilat Satellite announces SkyEdge IV platform enables SES's O3b mPOWER system - Gilat Satellite Networks announced that its SkyEdge IV platform is enabling SES's O3b mPOWER System to deliver high-performance connectivity services. "SkyEdge IV enables SES to deliver high-performance GEO-MEO services," said Hagay Katz, Chief Product and Marketing Officer at Gilat. "We are proud to partner with SES, providing Gilat's most advanced platform to support the growing demand for multi-orbit satellite communication services."

07:27 EDT Gogo sees compound annual growth rate 15%-17% from 2023 to 2028 - The Company continues to expect that Gogo Galileo will contribute revenue beginning in 2025. Sees annual Adjusted EBITDA Margin reaching 40% in 2028; Free Cash Flow $150M-$200M in 2025, without the effect of the FCC Reimbursement Program.

07:27 EDT Orchard Therapeutics announces multiple presentations at ASGCT 2024 - Orchard Therapeutics (ORTX), recently acquired by Kyowa Kirin (KYKOF) with the goal of accelerating the delivery of new gene therapies to patients around the globe, announced four oral and four poster presentations from across its hematopoietic stem cell gene therapy platform will be featured at the 27th Annual Meeting of the American Society of Gene and Cell Therapy, ASGCT, taking place May 7-11, 2024, in Baltimore. Featured data include several accepted abstracts and an Oral Presidential Symposium supporting the safety and efficacy of atidarsagene autotemcel, as well as three presentations detailing neurological, skeletal, and other clinical outcomes from a proof-of-concept study of investigational OTL-203 in the Hurler subtype of mucopolysaccharidosis type I. In addition, Orchard Therapeutics will give an invited oral presentation highlighting the potential of OTL-104, a pre-clinical HSC gene therapy developed by its in-house research team, to address a severe and treatment refractory form of Crohn's disease.

07:24 EDT Draganfly launches newest product, FlexForce Modular FPV UAV system - Draganfly announces the launch of its newest product, the FlexForce Modular FPV UAV System, available exclusively to Government & Military buyers following a FPV UAV Demonstration and Training. "The importance and effectiveness of FPV drones have been demonstrated and are now a key tool for defense operations. Given our work and experience in Ukraine and with the Drone Racing League, we designed the Flexforce Modular FPV Drone platform to offer maximum flexibility and capabilities", said Cameron Chell, CEO of Draganfly, "We are thrilled at the performance and results of demonstrations and training process to our military customers and look forward to providing this product to them at scale."

07:23 EDT AirBoss of America announces proposed settlement of class action - AirBoss of America announced that, subject to court approval, it has reached a settlement of the class action lawsuit pending against the Company in Canada. As previously disclosed in the Company's December 16, 2022 press release, a statement of claim was issued in the Ontario Superior Court of Justice against AirBoss and several named officers. The proceedings were commenced by Jonathan A. Callowhill and Shane Chambers, who sought an order for leave to proceed under the Securities Act, certifying the proceeding as a class proceeding and appointing them as representative plaintiffs. The plaintiffs sought, among other relief, a declaration that the Company made misrepresentations contrary to the Securities Act during a period extending from November 9, 2021 to September 6, 2022, as well as unspecified damages. Following a mediation between the plaintiffs and the defendants, the parties entered into a settlement agreement to resolve this matter. The plaintiffs will file a motion to establish a process for court approval of the Settlement. None of the defendants are admitting any liability, wrongdoing, or fault as part of the Settlement. If a preliminary order is granted by the Court, the plaintiffs will send notice of the Settlement to potential class members. Subject to certain conditions set forth in the Settlement, the parties expect to seek final approval of the Settlement from the Court after the applicable notice periods. The Settlement will not be final unless the Court grants final approval. The Company cannot provide any assurance that the Settlement will obtain the necessary approvals and satisfy the conditions and requirements necessary for it to become final. The Settlement, if approved, is within our insured limits and will not result in any direct financial impact to the Company.

07:21 EDT Cronos Group enters United Kingdom cannabis market - Cronos Group announced that it is expanding its medical brand, PEACE NATURALS, into the United Kingdom market with its first shipment of cannabis flower to GROW Pharma. Cronos will provide high-quality premium cannabis products, which have become synonymous globally with the PEACE NATURALS brand, to patients in the UK through this partnership.

07:20 EDT Antelope Enterprise Holdings reschedules 2H, 2023 earnings conference call - Antelope Enterprise Holdings will reschedule its conference call that was scheduled for Tuesday, May 7, 2024 at 8:00 am ET. Further details will be forthcoming as to the new conference call date and time.

07:18 EDT Verve Therapeutics announces dosing of first patient in VERVE-102 trial - Verve Therapeutics announced that the first patient has been dosed with VERVE-102 in the Heart-2 Phase 1b clinical trial. "Dosing the first patient in the Heart-2 Phase 1b clinical trial for VERVE-102 is an important step in the continued progress of our pipeline," said Sekar Kathiresan, M.D., co-founder and chief executive officer of Verve Therapeutics. "VERVE-102 is designed to turn off the PCSK9 gene with a goal of durably lowering LDL-C in patients living with either HeFH or premature CAD, and we look forward to evaluating the safety and preliminary efficacy data of VERVE-102 in the Heart-2 trial. With Clinical Trial Applications cleared in Canada and the United Kingdom, we are actively enrolling patients in the Heart-2 trial and expect to provide a data update on our PCSK9 program in 2025."

07:16 EDT Prelude Therapeutics sees cash runway into 2026 - Cash, cash equivalents and marketable securities as of March 31, 2024 were $201.9 million. The Company anticipates that its existing cash, cash equivalents and marketable securities will fund Prelude's operations into 2026.

07:14 EDT Theriva Biologics sees cash runway into 1Q25 - As of March 31, 2024, Theriva Biologics reports $18.3 million in cash, which is expected to provide runway into the first quarter of 2025

07:10 EDT Crocs names Susan Healy as CFO, succeeding Anne Mehlman - Crocs announced the appointment of Susan Healy as Executive Vice President and CFO of Crocs, effective June 3. Healy succeeds Anne Mehlman, who was recently appointed President of the Crocs Brand. Mehlman will continue to serve as CFO until Healy's start date. Healy will join the executive leadership team and report directly to Andrew Rees, CEO. Healy joins Crocs from IAA, Inc., a global marketplace for automotive buyers and sellers, where she served as CFO and led the company through its $7B merger with Ritchie Bros.

07:07 EDT Zentalis announces anticipated upcoming milestones - 1H 2024: Presentation of final results of Phase 1 azenosertib + chemotherapy trial in R/R osteosarcoma at 2024 ASCO Annual Meeting 2H 2024: Presentation of final results of Phase 1b azenosertib monotherapy trial in solid tumors; Topline data from Phase 1/2 MAMMOTH azenosertib + PARP inhibitor and azenosertib monotherapy trial in platinum resistant ovarian cancer in partnership with GSK; Presentation of initial data from Phase 1 azenosertib + BEACON regimen trial in BRAF mutant metastatic colorectal cancer in partnership with Pfizer; Initial data from Phase 1 azenosertib + ZN-d5 trial in R/R AML; Additional details on design of planned registration-enabling trial of azenosertib in PSOC in the 1L maintenance setting. 1H 2025: Topline data from registration-enabling Phase 2 DENALI study of azenosertib monotherapy in platinum resistant high-grade serous ovarian cancer 2H 2025: Topline data from registration-enabling Phase 2 TETON study of azenosertib monotherapy in recurrent or persistent USC. 2025: Initiate registration-enabling trial of azenosertib in PSOC in the 1L maintenance setting. 2026: First NDA for azenosertib in a gynecologic malignancy

06:55 EDT TopBuild announces $1B share repurchase authorization

06:49 EDT Bloomin' Brands announces CEO David Deno to retire - Bloomin' Brands announced that David Deno, CEO, will be retiring after 12 years with the company, including the last five years as CEO and a member of the Board of Directors. Deno will continue in his current role until a successor is named and a successful transition period is completed. The company's Board of Directors will conduct a search for Deno's successor.

06:43 EDT Nintendo reports 2023 hardware units sold 15.7M, down 12.6% y-o-y - The company said, "Looking at the Nintendo Switch business for the full fiscal year, good sales were posted for The Legend of Zelda: Tears of the Kingdom, which sold 20.61 million units, for Super Mario Bros. Wonder, which sold 13.44 million units and for Pikmin 4, which sold 3.48 million units. In addition, the April 2023 release of The Super Mario Bros. Movie positively impacted sales of Mario related titles, such as Mario Kart 8 Deluxe which recorded sales of 8.18 million units. As a result of these factors, the total number of million-seller titles during the period was 31, including titles from other software publishers. Hardware sales for this period totaled 15.70 million units, and software sales totaled 199.67 million units. While this represents a decrease from the previous fiscal year, sales are steady for a platform in its eighth year after launch. Turning to the digital business for our dedicated video game platform, downloadable versions of packaged software and add-on content for Nintendo Switch sold well, and revenue related to Nintendo Switch Online also increased. Digital sales reached 443.3 billion yen, helped also by the depreciation of the yen. In the mobile and IP related business, sales totaled 92.7 billion yen bolstered mainly by the generation of revenue related to The Super Mario Bros. Movie during this term. The end result is that overall sales reached 1,671.8 billion yen, with sales outside Japan of 1,309.2 billion yen accounting for 78.3% of that total, and operating profit was 528.9 billion yen. Ordinary profit came to 680.4 billion yen, mainly due to a substantial increase in foreign exchange gains and interest income, and net profit attributable to owners of parent totaled 490.6 billion yen."

06:32 EDT UBS sees Q2 low-to-mid single digit decline in Global Wealth Management NII - The company said, "Although monetary easing is expected in the Eurozone, the US and Switzerland, the timing and magnitude of rate cuts by central banks are unclear, as inflation remains above their target range. In addition, the ongoing geopolitical tensions, combined with consequential elections in several major economies, continue to create uncertainty regarding the macroeconomic and geopolitical outlooks. In the second quarter of 2024, we expect a low-to-mid single-digit decline in net interest income in Global Wealth Management, due to moderately lower lending and deposit volumes and lower interest rates in Switzerland, partly offset by additional revenues, primarily from higher US dollar rates, combined with our repricing efforts. We expect a mid-to-high single-digit decrease in net interest income in Personal & Corporate Banking in US dollar terms, as the Swiss central bank's interest rate cut in March 2024 takes effect for a full quarter. In line with our strategy to actively reduce assets and costs in Non-core and Legacy, we continue to expect revenues in the closing out of any positions to approximately reflect their current book value. We also expect our reported revenues to include around USD 0.6bn of pull-to-par and other PPA accretion effects, while we incur around USD 1.3bn of integration-related expenses. The tax rate for the second quarter is expected to return to more elevated levels, with our effective tax rate still expected to be around 40% by the end of 2024. In addition to executing on our integration plans, we will remain focused on serving our clients, following through on our strategy, investing in our people and remaining a pillar of economic support in the communities where we live and work."

06:29 EDT UBS expects to complete Credit Suisse merger on May 31 - The company said, "We expect to complete the merger of UBS AG and Credit Suisse AG on 31 May 2024, subject to remaining regulatory approvals. The transition to a single US intermediate holding company is planned for the second quarter of 2024, and the merger of Credit Suisse AG and UBS Switzerland AG continues to be planned for the third quarter of 2024, both also subject to remaining regulatory approvals. These critical milestones will facilitate the migration of clients onto UBS platforms beginning later this year, and unlock the next phase of the cost, capital, funding and tax benefits from the second half of 2024, and by the end of 2025 and into 2026."

06:19 EDT BP sees 2024 reported, underlying upstream production slightly higher vs. 2023 - The company said, "bp continues to expect both reported and underlying upstream production* to be slightly higher compared with 2023. Within this, bp continues to expect underlying production from oil production & operations to be higher and production from gas & low carbon energy to be lower. In its customers business, bp continues to expect growth from convenience, including a full year contribution from TravelCenters of America; a stronger contribution from Castrol underpinned by volume growth in focus markets; and continued margin growth from bp pulse driven by higher energy sold. In addition, bp continues to expect fuels margin to remain sensitive to the cost of supply. In products, bp continues to expect a lower level of industry refining margins, with realized margins impacted by narrower North American heavy crude oil differentials. bp continues to expect refinery turnaround activity to have a similar impact on both throughput and financial performance compared to 2023, with phasing of activity in 2024 heavily weighted towards the second half. bp continues to expect the other businesses & corporate underlying annual charge to be around $1.0 billion for 2024. The charge may vary from quarter to quarter. bp continues to expect the depreciation, depletion and amortization to be slightly higher than 2023. bp continues to expect the underlying ETR for 2024 to be around 40% but it is sensitive to the impact that volatility in the current price environment may have on the geographical mix of the group's profits and losses. bp continues to expect capital expenditure for 2024 to be around $16 billion, but now expects the phasing to be split broadly evenly between the first half and the second half. bp continues to expect divestment and other proceeds of $2-3 billion in 2024, weighted towards the second half. Having realized $18.2 billion of divestment and other proceeds since the second quarter of 2020, bp continues to expect to reach $25 billion of divestment and other proceeds between the second half of 2020 and 2025. bp continues to expect Gulf of Mexico oil spill payments for the year to be around $1.2 billion pre-tax including $1.1 billion pre-tax paid during the second quarter."

06:16 EDT BP announces further $1.75B share buyback - 1Q24 $1.75 billion share buyback announced as part of our $3.5 billion commitment for the first half of 2024; Dividend per ordinary share of 7.270 cents. The $1.75 billion share buyback programme announced with the fourth quarter results was completed on 3 May 2024.

06:13 EDT BP sees 2024, 2025 capex around $16B per annum - The company said, "bp continues to invest with discipline and a returns focused approach in our transition growth engines and in our oil, gas and refining businesses. For 2024 and 2025 we expect capital expenditure of around $16 billion per annum."

06:07 EDT Trump Media appoints Sewmple, Marchal & Cooper, LLP as auditor - Trump Media & Technology Group on Monday announced the appointment of Semple, Marchal & Cooper, LLP as its independent registered public accounting firm, effective May 4, 2024. TMTG said the appointment was made after a detailed evaluation process and that it anticipates seeking a limited extension of the deadline for its upcoming 10-Q by filing a Form 12b-25 no later than one business day after the original due date for such report. The Fly notes that the SEC on Friday banned BF Borgers, the firm that had previously been registered as the auditor for TMTG.

05:58 EDT Boeing Starliner launch called off following problem with valve - The launch of a Boeing (BA) spacecraft was been called off on Monday after an issue was found with a component, hours after the FAA opened their second investigation into the company this year. The CST-100 Starliner spacecraft was due to be launched on Monday evening from Cape Canaveral, Florida, to carry two astronauts to the International Space Station, but the United Launch Alliance, a joint venture between Boeing and Lockheed Martin (LMT), stopped the launch due to a problem with an oxygen relief valve on part of the rocket "out of an abundance of caution for the safety of the flight and pad crew." ULA is targeting the next launch attempt no earlier than Friday, May 10. Reference Link

05:16 EDT KKR, Marriott launch into midscale hospitality space in Japan - KKR (KKR) and Marriott (MAR) announced the launch of each company's foray into the midscale hospitality space in Japan, which follows KKR's completion of the acquisition of Unizo Hotel and a portfolio of 14 hotels in Japan from Unizo Holdings. The 14 hotels will be converted to Four Points Express by Sheraton. This marks Marriott's entry into the affordable midscale segment in Japan and the brand's debut in Asia Pacific following its global launch in this space in 2023. The portfolio of 14 hotels is located in major tourist destinations in 10 cities across Japan, including Hakodate, Morioka, Utsunomiya, Yokohama, Kanazawa, Nagoya, Osaka, Kyoto, Kobe, and Hakata. The properties are expected to open in the second half of 2024, adding more than 3,600 new rooms to KKR's and Marriott's respective hotel portfolios in Japan. Additional details of the transaction have not been disclosed.

05:08 EDT Faraday Future issues statement on YT Jia social media post - Faraday Future released the following statement regarding a recent social media post: "The Company is aware that a video relating to the Company has been released on a social media outlet in China by YT Jia, in his individual capacity and not in his capacity as an officer of the Company. The statements made in the video have not been approved by the Company and none of such statements should be attributed or attributable to the Company. Further, while the Company understands that the video indicates contemplation by Mr. Jia of the possibility of serving as co-Chief Executive Officer of the Company subject to appointment by the Company's Board of Directors, and appreciates his offer of service, at this time the Company's Board is not considering the appointment of Mr. Jia as co-CEO."